Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-invasive TRanscutaneous Cervical Vagus Nerve Stimulation as a Treatment for Acute Stroke; Safety and Feasibility Study (TR-VENUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03733431
Recruitment Status : Not yet recruiting
First Posted : November 7, 2018
Last Update Posted : February 1, 2019
Sponsor:
Collaborators:
Turkish Neurological Society
ElectroCore INC
Information provided by (Responsible Party):
Ethem Murat Arsava, Hacettepe University

Brief Summary:
This study aims to determine safety and feasibility of non-invasive transcutaneous cervical Vagus nerve stimulation (nVNS) when delivered promptly after clinical diagnosis of acute stroke. Vagus nerve stimulation will be performed via GammaCore® device. A total of 60 patients will be randomized to each of 3 different groups; 'standard dose' vagal stimulation, 'high dose' vagal stimulation, and 'sham stimulation' (1:1:1 ratio). Adverse device events, serious adverse device events, and feasibility of vagal nerve stimulation at the setting of acute stroke will be evaluated. The study will be performed in a multi-center fashion among stroke centers within TurkStrokeNet Network.

Condition or disease Intervention/treatment Phase
Stroke, Acute Stroke, Ischemic Stroke Stroke, Hemorrhagic Device: Gammacore device Device: Gammacore sham device Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Non-invasive TRanscutaneous Cervical Vagus Nerve Stimulation as a Treatment for Acute Stroke; Safety and Feasibility Study
Estimated Study Start Date : March 2019
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
Active Comparator: Standard dose vagal stimulation
A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
Device: Gammacore device
Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.

Active Comparator: High dose vagal stimulation
A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
Device: Gammacore device
Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.

Sham Comparator: Sham stimulation
A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
Device: Gammacore sham device
Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.




Primary Outcome Measures :
  1. Cardiovascular effects, clinical worsening or death (primary safety measure) [ Time Frame: 24 hours ]

    any of the following:

    • severe bradycardia (HR ≤50/min) during treatment application
    • significant decrease in arterial blood pressure (≥20 mmHg decrease in mean arterial blood pressure) during treatment application
    • neurological worsening (progression of neurologic deficit as shown by ≥ 4 points increase in NIH Stroke Scale Score) within 24 hours
    • death within 24 hours


Other Outcome Measures:
  1. Proportion of treatment eligible patients (feasibility measure 1) [ Time Frame: 6 hours ]
    Proportion of eligible patients in whom nVNS can be started within the first 6 hours.

  2. Proportion of patients completing all pre-specified treatment doses (feasibility measure 2) [ Time Frame: 12 hours ]
    Proportion of enrolled patients who receive all the pre-specified treatment doses per protocol.

  3. Stroke onset to treatment time (feasibility measure 3) [ Time Frame: 6 hours ]
    Time from stroke onset to administration of the first dose of nVNS.

  4. Early neurological outcome (efficacy measure 1) [ Time Frame: 24 hours ]
    Proportion of patients with NIHSS score≤4 or improvement of baseline NIHSS score ≥8 at 24 hours

  5. Early tissue outcome (efficacy measure 2) [ Time Frame: 24 hours ]
    Delta infarct volume between baseline DWI and 24 hr MRI.

  6. Local reaction at application site (secondary safety measure 1) [ Time Frame: 12 hours ]
    Local irritation or skin reaction during treatment application

  7. Acute coronary syndrome (secondary safety measure 2) [ Time Frame: 24 hours ]
    Acute coronary syndrome

  8. Symptomatic intracerebral hemorrhage (secondary safety measure 3) [ Time Frame: 24 hours ]
    Symptomatic intracerebral hemorrhage: ≥ 4 points increase in NIH Stroke Scale Score (NIHSS) together with a PH2 (parenchymal hematoma-2) type intracerebral hemorrhage

  9. Death, clinical worsening, and acute coronary syndrome (secondary safety measure 4) [ Time Frame: 24 hours ]
    Combined outcome of death, clinical worsening, and acute coronary syndrome

  10. New ischemic lesion or increase in hemorrhage (secondary safety measure 5) [ Time Frame: 24 hours ]
    New, spatially distinct remote ischemic lesion outside the arterial territory of the index lesion on MRI at 24 hours or greater than 30% increase in hemorrhage volume from baseline CT to 24 hour MRI in the subset with intracerebral hemorrhage

  11. Serious adverse device event (SADE) rate (secondary safety measure 6) [ Time Frame: 24 hours ]
    Serious adverse device event (SADE) rate at 24 hours



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients who are older than 18 years old who have been admitted to neurological intensive care or stroke units with ischemic or hemorrhagic stroke
  • Patients with symptom onset time within 6 hours or with unknown time of onset and no evidence of acute ischemia on fluid attenuation inversion recovery (FLAIR) imaging
  • Patients who have given written informed consent prior to undertaking any study-related procedure.

Exclusion Criteria:

  • Patients who have a pre-stroke disability ≥ 2 according to the modified Rankin Score
  • Patients who have a NIH Stroke Scale/Score (NIHSS) ≤ 4 or ≥30
  • Patients who have a NIHSS item 1a ≥2
  • Patients who have experienced early dramatic neurological improvement (NIHSS score improvement ≥8) prior to study randomization suggesting resolution of signs/symptoms of stroke
  • Patients with classical lacunar syndrome
  • Patients who have local infection, rash or space occupying lesion at the stimulation site
  • Patients with a prior injury to the vagus nerve (cervical vagotomy)
  • Patients with conditions that make the positioning of the device not possible such as tonic head deviation or involuntary movements of the head and neck
  • Patients using medications that can interfere with central neurotransmitter mechanisms potentially involved in the central vagal pathway (complete list is provided below under concomitant medications)
  • Patients with known severe (>90% stenosis) bilateral carotid artery disease
  • Patients with known carotid hypersensitivity
  • Patients who had undergone bilateral carotid endarterectomy or neck surgery involving the region of carotid triangle
  • Patients who have low blood pressure (Baseline SBP≤100 mmHg or DBP≤60 mmHg)
  • Patients who have slow heart rate (Baseline HR≤60/min)
  • Patients who have high blood pressure (SBP>220 mmHg or DBP>130 mmHg) despite initial line of treatment
  • Patients who have been involved in any investigational study within the previous 90 days
  • Patients who have any terminal illness such that the patient would not be expected to survive more than 90 days
  • Pregnant women
  • Patients with severe hypoglycemia at admission (<60 mg/dl)
  • Patient experiencing seizures
  • Patients with baseline ECG showing first-degree AV block; second- or third-degree atrio-ventricular block with no pacemaker/ICD in place; or ventricular tachycardia/fibrillation
  • Patients with digitalis toxicity
  • Patients who are suspected to have an acute coronary syndrome after clinical evaluations (Clinical, ECG, or any related biomarker)
  • Patients who are scheduled to have an emergent carotid artery angioplasty stenting or endarterectomy
  • Patients implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
  • Patients implanted with metal cervical spine hardware or having a metallic implant near the GammaCore stimulation site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03733431


Contacts
Layout table for location contacts
Contact: Ethem M Arsava, MD 00905323355172 arsavaem@hotmail.com
Contact: Mehmet A Topcuoglu, MD 00905365753634 matopcuoglu@yahoo.com

Sponsors and Collaborators
Turkish Stroke Research and Clinical Trials Network
Turkish Neurological Society
ElectroCore INC
Investigators
Layout table for investigator information
Principal Investigator: Ethem M Arsava, MD Hacettepe University
Principal Investigator: Mehmet A Topcuoglu, MD Hacettepe University
Study Chair: Hakan Ay, MD Massachusetts General Hospital, Harvard University

Layout table for additonal information
Responsible Party: Ethem Murat Arsava, Professor of Neurology, Hacettepe University
ClinicalTrials.gov Identifier: NCT03733431     History of Changes
Other Study ID Numbers: TR-VENUS
First Posted: November 7, 2018    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Ethem Murat Arsava, Hacettepe University:
vagal nerve stimulation

Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases